The report states EBITDA declined 8% YoY despite 11% sales growth due to higher costs, but maintains ADD with a revised target price.
Read this note →Lupin Limited
NSE LUPIN BSE 500257 INE326A01037
0 filings · 0 analysed
2,025.00
+2.49%
over 1 year
-
HSIE Results Daily 05 Nov 26 HSIE
The report states EBITDA declined 8% YoY despite 11% sales growth due to higher costs, but maintains ADD with a revised target price.
-
The Momentum Swing section lists a Buy call on Lupin November futures with stop loss 1,937 and targets 2,025 and 2,060.
-
The report notes the US FDA concluded an inspection at its Goa facility, closing with a Form-483 citing one observation.
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects a 14% YoY EBITDA decline due to competition-led price erosion in Tolvaptan and gMyrbetriq, listing it as a muted performer.
-
The note reports Lupin launched Formoflo-G MDI, a fixed-dose triple combination inhaler for COPD in India.
-
The note reports Lupin launched Formoflo-G MDI, a triple-combination inhaler for COPD management in India.
-
The report notes Lupin's US sales are expected to dip 18% sequentially due to competition in Mirabegron and Tolvaptan, with an 11% YoY EBITDA decline.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 05 Nov 2026, 06:50 | long | 2,008.60 | 2,250.00 | 1,988.10 | -8% | open by 2027-11-05 |
| Sharekhan (Mirae Asset Sharekhan) | 28 Oct 2026, 16:42 | long | 1,972.70 | 2,025.00 | 1,996.50 | 46% | hit |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 2,012.90 | 2,630.00 | 1,988.10 | -4% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The Momentum Swing section lists a Buy call on Lupin November futures with stop loss 1,937 and targets 2,025 and 2,060.
Read this note →The report notes the US FDA concluded an inspection at its Goa facility, closing with a Form-483 citing one observation.
Read this note →The report expects a 14% YoY EBITDA decline due to competition-led price erosion in Tolvaptan and gMyrbetriq, listing it as a muted performer.
Read this note →The note reports Lupin launched Formoflo-G MDI, a triple-combination inhaler for COPD management in India.
Read this note →The note reports Lupin launched Formoflo-G MDI, a fixed-dose triple combination inhaler for COPD in India.
Read this note →The report notes Lupin's US sales are expected to dip 18% sequentially due to competition in Mirabegron and Tolvaptan, with an 11% YoY EBITDA decline.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief